Insider Transactions in Q3 2023 at Harrow Health, Inc. (HROW)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 20
2023
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,983
+0.17%
|
$83,762
$14.49 P/Share
|
|
Sep 19
2023
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
14,017
+0.39%
|
$196,238
$14.65 P/Share
|
|
Aug 14
2023
|
Martin A. Makary Director |
BUY
Open market or private purchase
|
Direct |
20,000
+30.77%
|
$320,000
$16.92 P/Share
|
|
Aug 14
2023
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
5,800
+0.29%
|
$98,600
$17.05 P/Share
|
|
Jul 18
2023
|
John P. Saharek CEO of ImprimisRx |
SELL
Payment of exercise price or tax liability
|
Direct |
109,080
-32.93%
|
$1,963,440
$18.23 P/Share
|
|
Jul 18
2023
|
John P. Saharek CEO of ImprimisRx |
BUY
Exercise of conversion of derivative security
|
Direct |
277,200
+45.56%
|
-
|
|
Jul 18
2023
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
299,968
-12.99%
|
$5,399,424
$18.23 P/Share
|
|
Jul 18
2023
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
762,300
+24.82%
|
-
|
|
Jul 18
2023
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
136,350
-20.34%
|
$2,454,300
$18.23 P/Share
|
|
Jul 18
2023
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
346,500
+34.07%
|
-
|